Search

Displaying results 4331 - 4340 of 8575 in total
  1. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

  2. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).

  3. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based

  4. Drug

    Beraprost

    go.drugbank.com/drugs/DB05229
    Investigational

    Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

  5. Drug

    Dasotraline

    go.drugbank.com/drugs/DB12305
    Investigational

    Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, ...

  6. Drug

    Fluorodopa (18F)

    go.drugbank.com/drugs/DB13848
    ApprovedInvestigational

    Fluorodopa F 18 is a fluorinated analog of [levodopa] used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes.

  7. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.

  8. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.

  9. Drug

    COVID19 s-vax loaded autologous dendritic cell vaccine

    go.drugbank.com/drugs/DB15814
    Experimental

    This vaccine was developed and tested by Beijing TIL Therapeutics. … These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.

  10. Drug

    BMS-986251

    go.drugbank.com/drugs/DB19007
    Investigational

    BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis